Mark E Burkard Selected Research

Breast Neoplasms (Breast Cancer)

3/2024	The Right Dose: Results of a Patient Advocate-Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life.
10/2023	Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles.
1/2023	Exceptional Response to Crizotinib With Subsequent Response to Cabozantinib in Metastatic, ROS1-GOPC Fusion-Mutated Breast Cancer.
1/2022	Classes of therapeutics to amplify the immune response.
12/2021	Paclitaxel Induces Micronucleation and Activates Pro-Inflammatory cGAS-STING Signaling in Triple-Negative Breast Cancer.
10/2021	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
9/2021	Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel.
3/2021	Breast cancer immunotherapy: current biomarkers and the potential of in vitro assays.
2/2021	High nuclear TPX2 expression correlates with TP53 mutation and poor clinical behavior in a large breast cancer cohort, but is not an independent predictor of chromosomal instability.
1/2020	Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark E Burkard Research Topics

Disease

30	Neoplasms (Cancer) 07/2023 - 12/2010
20	Breast Neoplasms (Breast Cancer) 03/2024 - 01/2012
5	Chromosomal Instability (Chromosome Stability) 10/2023 - 11/2020
3	Triple Negative Breast Neoplasms 12/2021 - 01/2016
2	Adenocarcinoma 01/2024 - 01/2024
2	Lung Neoplasms (Lung Cancer) 02/2023 - 01/2020
2	Neoplasm Metastasis (Metastasis) 01/2023 - 02/2021
2	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 01/2016
1	Pancreatic Neoplasms (Pancreatic Cancer) 08/2023
1	Microsatellite Instability 02/2023
1	Bites and Stings (Sting) 12/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2020
1	Diarrhea 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Thyroid Neoplasms (Thyroid Cancer) 01/2020
1	Hyponatremia 01/2020
1	medullary Thyroid cancer 01/2020
1	Melanoma (Melanoma, Malignant) 01/2018
1	Exanthema (Rash) 12/2017
1	Pathologic Complete Response 11/2017
1	Hot Flashes 01/2017
1	Pain (Aches) 01/2017
1	Nausea 01/2017
1	Hypokalemia 01/2017
1	Myalgia 01/2017
1	Polyploidy 01/2016
1	Fever (Fevers) 01/2012

Drug/Important Bio-Agent (IBA)

8	Biomarkers (Surrogate Marker)IBA 02/2023 - 01/2020
4	Paclitaxel (Taxol)FDA LinkGeneric 10/2023 - 03/2014
3	cabozantinibIBA 01/2023 - 01/2020
3	Hormones (Hormone)IBA 10/2021 - 07/2012
3	RNA (Ribonucleic Acid)IBA 02/2021 - 01/2021
2	Immune Checkpoint InhibitorsIBA 02/2023 - 12/2021
2	CrizotinibIBA 01/2023 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2020
2	Taxoids (Taxanes)IBA 12/2021 - 09/2021
2	Aromatase InhibitorsIBA 10/2021 - 07/2012
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2016
2	Estrogens (Estrogen)FDA Link 11/2017 - 01/2017
2	MK 2206IBA 11/2017 - 01/2016
1	PoisonsIBA 10/2023
1	pembrolizumabIBA 02/2023
1	Aurora Kinase BIBA 01/2022
1	Immune Checkpoint ProteinsIBA 12/2021
1	cyclic guanosine monophosphate-adenosine monophosphateIBA 12/2021
1	eribulin FDA Link 12/2021
1	Vinorelbine (Navelbine)FDA LinkGeneric 12/2021
1	entinostat (MS 275)IBA 10/2021
1	exemestane (Aromasin)FDA Link 10/2021
1	human ERBB2 proteinIBA 10/2021
1	Histone Deacetylase InhibitorsIBA 10/2021
1	taxaneIBA 09/2021
1	Small Cytoplasmic RNAIBA 02/2021
1	theasinensin AIBA 01/2021
1	InterferonsIBA 11/2020
1	vandetanib (ZD6474)IBA 01/2020
1	Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2020
1	pericentrinIBA 01/2020
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020
1	AntibodiesIBA 01/2020
1	selpercatinibIBA 01/2020
1	dactolisibIBA 01/2019
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2019
1	Everolimus FDA Link 01/2019
1	sapanisertibIBA 01/2019
1	centrinone-BIBA 01/2018
1	SteroidsIBA 12/2017
1	Capecitabine (Xeloda)FDA Link 12/2017
1	Fluorouracil (Carac)FDA LinkGeneric 12/2017
1	ProdrugsIBA 12/2017
1	Sunscreening Agents (Sunscreens)IBA 12/2017
1	Estrogen ReceptorsIBA 11/2017
1	Prednisone (Sone)FDA LinkGeneric 11/2017
1	Anastrozole (Arimidex)FDA LinkGeneric 11/2017
1	Goserelin (Zoladex)FDA Link 11/2017
1	AndrogensIBA 01/2017
1	Anaphase-Promoting Complex-CyclosomeIBA 01/2017
1	orteronelIBA 01/2017
1	Androgen Receptors (Androgen Receptor)IBA 01/2017
1	AntimetabolitesIBA 01/2016
1	QuinoxalinesIBA 01/2016
1	Hypoxanthine Phosphoribosyltransferase (Hypoxanthine Guanine Phosphoribosyltransferase)IBA 01/2016
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2016
1	Carcinoembryonic AntigenIBA 01/2016
1	Lapatinib (GW572016)FDA Link 01/2016
1	Estrogen Receptor betaIBA 01/2016
1	AzaguanineIBA 01/2016
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2014
1	Docetaxel (Taxotere)FDA Link 06/2014
1	CalciumIBA 07/2012
1	Polo-Like Kinase 1IBA 06/2012
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2012

Therapy/Procedure

15	Therapeutics 03/2024 - 12/2010
8	Drug Therapy (Chemotherapy) 01/2023 - 01/2012
5	Immunotherapy 03/2024 - 03/2021
3	Precision Medicine 07/2023 - 01/2017
2	Pancreatectomy 01/2024 - 01/2024
1	Neoadjuvant Therapy 08/2023
1	Adjuvant Chemotherapy 01/2014